Fraxetin suppresses the proliferation, migration, and invasion of ovarian cancer cells by inhibiting the TLR4/STAT3 signaling pathway

References

• Knutson KL, Karyampudi L, Lamichhane P, et al. Targeted immune therapy of ovarian cancer. Cancer Metastasis Rev. 2015;34(1):53–74.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Au KK, Josahkian JA, Francis JA, et al. Current state of biomarkers in ovarian cancer prognosis. Future Oncol. 2015;11(23):3187–3195.
   PubMed Web of Science ®Google Scholar
• Chen L, Wang J, Wu J, et al. Indirubin suppresses ovarian cancer cell viabilities through the STAT3 signaling pathway. Drug Des Devel Ther. 2018;12:3335–3342.
   PubMed Web of Science ®Google Scholar
• Ibrahim EY, Ehrlich BE. Prevention of chemotherapy-induced peripheral neuropathy: a review of recent findings. Crit Rev Oncol Hematol. 2020;145:102831.
   PubMed Web of Science ®Google Scholar
• Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012;2375(3):311–335.
   PubMed Web of Science ®Google Scholar
• Ren S, Xing Y, Wang C, et al. Fraxetin inhibits the growth of Colon adenocarcinoma cells via the janus kinase 2/signal transducer and activator of transcription 3 signalling pathway. Int J Biochem Cell Biol. 2020;125:105777.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhuang D, Feng W, et al. Fraxetin inhibits interleukin-1β-induced apoptosis, inflammation, and matrix degradation in chondrocytes and protects rat cartilage in vivo. Saudi Pharm J. 2020;28(12):1499–1506.
   PubMed Web of Science ®Google Scholar
• Kashani B, Zandi Z, Bashash D, et al. Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid). Cancer Chemother Pharmacol. 2020;85(1):47–59.
   PubMed Web of Science ®Google Scholar
• Gruffaz M, Vasan K, Tan B, et al. TLR4-mediated inflammation promotes KSHV-induced cellular transformation and tumorigenesis by activating the STAT3 pathway. Cancer Res. 2017;77(24):7094–7108.
   PubMed Web of Science ®Google Scholar
• Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68(18):3033–3046.
   PubMed Web of Science ®Google Scholar
• Derycke LD, Bracke ME. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol. 2004;48(5–6):463–476.
   PubMed Web of Science ®Google Scholar
• Tian Y, Qi P, Niu Q, et al. Combined snail and E-cadherin predicts overall survival of cervical carcinoma patients: comparison among various epithelial-mesenchymal transition proteins. Front Mol Biosci. 2020;7:22.
   PubMed Web of Science ®Google Scholar
• Yao RR, Li JH, Zhang R, et al. M2-polarized tumor-associated macrophages facilitated migration and epithelial-mesenchymal transition of HCC cells via the TLR4/STAT3 signaling pathway. World J Surg Oncol. 2018;16(1):9.
   PubMedGoogle Scholar
• Liao DJ, Thakur A, Wu J, et al. Perspectives on c-Myc, cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy. Crit Rev Oncog. 2007;13(2):93–158.
   PubMedGoogle Scholar
• Zhao H, Feng Y, Wei C, et al. Colivelin rescues ischemic neuron and axons involving JAK/STAT3 signaling pathway. Neuroscience. 2019;416:198–206.
   PubMed Web of Science ®Google Scholar
• Duff D, Long A. Roles for RACK1 in cancer cell migration and invasion. Cell Signal. 2017;35:250–255.
   PubMed Web of Science ®Google Scholar
• van Roy F. Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat Rev Cancer. 2014;14(2):121–134.
   PubMed Web of Science ®Google Scholar
• De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97–110.
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–890. Nov 25
   PubMed Web of Science ®Google Scholar
• Saitoh M. Involvement of partial EMT in cancer progression. J Biochem. 2018;164(4):257–264.
   PubMed Web of Science ®Google Scholar
• Wang Y, Shi J, Chai K, et al. The role of snail in EMT and tumorigenesis. Curr Cancer Drug Targets. 2013;13(9):963–972. Nov
   PubMed Web of Science ®Google Scholar
• Lu L, Chen Z, Lin X, et al. Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of snail. Cell Death Differ. 2020;27(1):255–268.
   PubMed Web of Science ®Google Scholar
• Lin Y, Wu Y, Li J, et al. The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. EMBO J. 2010;29(11):1803–1816.
   PubMed Web of Science ®Google Scholar
• Dong C, Wu Y, Wang Y, et al. Interaction with Suv39H1 is critical for snail-mediated E-cadherin repression in breast cancer. Oncogene. 2013;32(11):1351–1362.
   PubMed Web of Science ®Google Scholar
• Leslie K, Lang C, Devgan G, et al. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res. 2006;66(5):2544–2552.
   PubMed Web of Science ®Google Scholar
• Zhang S, Li J, Xie P, et al. STAT3/c-Myc axis-mediated metabolism alternations of inflammation-related glycolysis involve with colorectal carcinogenesis. Rejuvenation Res. 2019;22(2):138–145.
   PubMed Web of Science ®Google Scholar
• Hsiao CC, Chen PH, Cheng CI, et al. Toll-like receptor-4 is a target for suppression of proliferation and chemoresistance in HepG2 hepatoblastoma cells. Cancer Lett. 2015;368(1):144–152.
   PubMed Web of Science ®Google Scholar
• Sanjari M, Kordestani Z, Safavi M, et al. Enhanced expression of cyclin D1 and C-myc, a prognostic factor and possible mechanism for recurrence of papillary thyroid carcinoma. Sci Rep. 2020;10(1):5100.
   PubMed Web of Science ®Google Scholar
• Ramos-García P, Gil-Montoya JA, Scully C, et al. An update on the implications of cyclin D1 in oral carcinogenesis. Oral Dis. 2017;23(7):897–912.
   PubMed Web of Science ®Google Scholar